

Estonia

Population (January 2013):	1 320 174
Human development Index (2013):	0.840
HAV vaccine recommendations:	HAV vaccination is not included in the national childhood immunisation programme. Vaccination is recommended for: <ol style="list-style-type: none"> 1. for the all population, especially for children and adults with chronic liver diseases (chronic hepatitis, cirrhosis, biliary atresia) 2. PWID 3. MSM 4. sewage workers 5. food business operators.
Seroprevalence studies by quality score:	score 0: 0 studies score 1: 1 studies score 2: 0 studies
Seroprevalence studies Timeframe:	2002

Seroprevalence assessment: **very low**
 Incidence assessment: **low**
 Susceptibility in adults: **high**

Only one study on HAV seroprevalence could be found on the Estonian population. According to this non-randomised study, conducted in 2002 among the general population, the HAV seroprevalence was around 40% at the age of 30 years; increasing to around 50% by the age of 50. Therefore, Estonia can be classified as a very low endemicity country in the present period.

Estonia_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2012			

Available incidence data from 1995 show a steady decrease from 250 cases per 100 000 to values mostly oscillating around 2 cases per 100 000 in the period 2006 to the present with a peak of 11 cases per 100 000 in 2011 (Estonia_Figure 1).


The susceptibility at 30 years is estimated to be around 60%, decreasing to around 50% in 50 year olds. Hence the overall susceptibility is estimated as high.

Estonia_Figure 1 (panel a). Summary of seroprevalence in Estonia, by age and time period.

Panel a.1: 1975–1989

No data available


Panel a.2: 1990–1999



Panel a.3: 2000–2013

No data available

Estonia_Figure 2. Reported incidence of hepatitis A in Estonia, 1985–2013*



* National data source: personal communication from ECDC National Focal Point/Operational Contact Point, Estonian Health Board

Bibliography

1. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. *J Travel Med.* 2007;14(3):181-7.
2. Tefanova V, TalloT, Katargina O, L. P. Shift in seroepidemiology of hepatitis A in Estonian population. 7th Nordic-Baltic Congress on Infectious Diseases; 18-20 September; Riga2006.